MSD Launches New Manufacturing Facilities In Singapore For Innovative Medicines And Vaccines As Part Of Up To Us$500 Million Multiyear Investment


MSD’s newly commissioned secondary packaging and sterile filling facility will increase production of immunotherapy for cancer patients in Singapore and the Asia Pacific region. With fully automated and semi-automated packaging lines, it will significantly increase production of MSD’s cancer immunotherapy and vaccines.

Article Summary

MSD announced the opening of a new secondary packaging facility to support the production of vaccines and biologics, including the company’s cancer immunotherapy products. The company also broke ground in Singapore for a new facility for manufacturing inhaler medicines of the next generation.

A US$500 million investment will be made over five years, starting in 2020, to build the new manufacturing facilities. A total of US$2 billion has also been invested in MSD’s Singapore manufacturing operations since 1997.

The opening of the new secondary packaging facility and ground-breaking for the inhaler production facility located at Tuas, was witnessed by Singapore’s Minister for Trade & Industry, Mr Gan Kim Yong who was the Guest-of-Honour, and Mr Robert Davis, Chief Executive Officer and President of MSD (known as Merck & Co., in the U.S. and Canada).


Fernando Otero, associate vice president, MSD Manufacturing Division, Singapore mentioned, “MSD is committed to Singapore as a strategic node in our company’s global manufacturing network with a focus on producing innovative medicines to treat chronic diseases and cancer as well as vaccines that prevent infectious diseases for patients living in Singapore and throughout the Asia Pacific region and beyond.”

“The talent, research, and technology capabilities that first attracted our company to Singapore has been a key incentive for our continuing investment. We’re delighted to further invest in building technologically advanced facilities and highly skilled manufacturing here,” he added. 

Goh Wan Yee, Senior Vice President & Head (Healthcare), Singapore Economic Development Board, said: “As the gateway to Asia Pacific, Singapore has the talent, infrastructure, and supply chain network for healthcare companies to innovate, manufacture, and commercialise products and solutions for the region. By tapping on Singapore’s deep capabilities in advanced manufacturing and digital, MSD’s latest expansion will enable it to produce more innovative medicines and vaccines to meet the region’s needs. We look forward to strengthening our long-term partnership with MSD, supporting its continued growth and creating more good job opportunities for Singaporeans.”

The investment is estimated to create over 100 new jobs over the next few years to support the new facility and multi-year investment plan, with many positions requiring advanced manufacturing and digital skills. This would bring the company’s total employees in Singapore to more than 1,800 over the next few years.  


About MSD

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. 


(Source: MSD, October 5, 2022)